CCL

Összesen 7 találat.
#/oldal:
Részletezés:
Rendezés:

1.

001-es BibID:BIBFORM103357
035-os BibID:(cikkazonosító)e27622 (WOS)000297555300037 (Scopus)81055129712
Első szerző:Kissling, Esther
Cím:I-MOVE Multi-Centre Case Control Study 2010-11 : overall and Stratified Estimates of Influenza Vaccine Effectiveness in Europe / Esther Kissling, Marta Valenciano, Jean Marie Cohen, Beatrix Oroszi, Anne-Sophie Barret, Caterina Rizzo, Pawel Stefanoff, Baltazar Nunes, Daniela Pitigoi, Amparo Larrauri, Isabelle Daviaud, Judit Krisztina Horvath, Joan O'Donnell, Thomas Seyler, Iwona Anna Paradowska-Stankiewicz, Pedro Pechirra, Alina Elena Ivanciuc, Silvia Jiménez-Jorge, Camelia Savulescu, Bruno Christian Ciancio, Alain Moren
Dátum:2011
ISSN:1932-6203
Megjegyzések:Background: In the third season of I-MOVE (Influenza Monitoring Vaccine Effectiveness in Europe), we undertook a multicentre case-control study based on sentinel practitioner surveillance networks in eight European Union (EU) member states to estimate 2010/11 influenza vaccine effectiveness (VE) against medically-attended influenza-like illness (ILI) laboratory-confirmed as influenza. Methods: Using systematic sampling, practitioners swabbed ILI/ARI patients within seven days of symptom onset. We compared influenza-positive to influenza laboratory-negative patients among those meeting the EU ILI case definition. A valid vaccination corresponded to > 14 days between receiving a dose of vaccine and symptom onset. We used multiple imputation with chained equations to estimate missing values. Using logistic regression with study as fixed effect we calculated influenza VE adjusting for potential confounders. We estimated influenza VE overall, by influenza type, age group and among the target group for vaccination. Results: We included 2019 cases and 2391 controls in the analysis. Adjusted VE was 52% (95% CI 30-67) overall (N = 4410), 55% (95% CI 29-72) against A(H1N1) and 50% (95% CI 14-71) against influenza B. Adjusted VE against all influenza subtypes was 66% (95% CI 15-86), 41% (95% CI -3-66) and 60% (95% CI 17-81) among those aged 0-14, 15-59 and ?60 respectively. Among target groups for vaccination (N = 1004), VE was 56% (95% CI 34-71) overall, 59% (95% CI 32-75) against A(H1N1) and 63% (95% CI 31-81) against influenza B. Conclusions: Results suggest moderate protection from 2010-11 trivalent influenza vaccines against medically-attended ILI laboratory-confirmed as influenza across Europe. Adjusted and stratified influenza VE estimates are possible with the large sample size of this multi-centre case-control. I-MOVE shows how a network can provide precise summary VE measures across Europe.
Tárgyszavak:Orvostudományok Egészségtudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:Plos One. - 6 : 11 (2011), p. 1-11. -
További szerzők:Valenciano, Marta Cohen, Jean Marie Oroszi Beatrix (1970-) (orvos, epidemiológus) Barret, Anne-Sophie Rizzo, Caterina Stefanoff, Pawel Nunes, Baltazar Pitigoi, Daniela Larrauri, Amparo Daviaud, Isabelle Horváth Judit Krisztina O'Donnell, Joan Seyler, Thomas Paradowska-Stankiewicz, Iwona Pechirra, Pedro Ivanciuc, Alina Elena Jiménez-Jorge, Silvia Savulescu, Camelia Ciancio, Bruno Moren, Alain
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

2.

001-es BibID:BIBFORM103354
035-os BibID:(WOS)000394454800001 (Scopus)85014105621
Első szerző:Kissling, Esther
Cím:Early 2016/17 vaccine effectiveness estimates against influenza A(H3N2) : I-MOVE multicentre case control studies at primary care and hospital levels in Europe / E. Kissling, M. Rondy, I-MOVE/I-MOVE+ study team
Dátum:2017
ISSN:1560-7917
Tárgyszavak:Orvostudományok Egészségtudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:Eurosurveillance. - 22 : 7 (2017), p. 1-9. -
További szerzők:Rondy, M. Oroszi Beatrix (1970-) (orvos, epidemiológus) I-MOVE/I-MOVE+ study team
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

3.

001-es BibID:BIBFORM103353
035-os BibID:(Scopus)85015354198 (WOS)000374833800004
Első szerző:Kissling, Esther
Cím:I-MOVE multicentre case-control study 2010/11 to 2014/15 : is there within-season waning of influenza type/subtype vaccine effectiveness with increasing time since vaccination? / E. Kissling, B. Nunes, C. Robertson, M. Valenciano, A. Reuss, A. Larrauri, J. M. Cohen, Beatrix Oroszi, C. Rizzo, A. Machado, D. Pitigoi, L. Domegan, I. Paradowska-Stankiewicz, U. Buchholz, A. Gherasim, I. Daviaud, J. K. Horváth, A. Bella, E. Lupulescu, J. O'Donnell, M. Korczyńska, A. Moren, I-MOVE case-control study team
Dátum:2016
ISSN:1560-7917
Megjegyzések:Since the 2008/9 influenza season, the I-MOVE multicentre case?control study measures influenza vaccine effectiveness (VE) against medically-attended influenza-like-illness (ILI) laboratory confirmed as influenza. In 2011/12, European studies reported a decline in VE against influenza A(H3N2) within the season. Using combined I-MOVE data from 2010/11 to 2014/15 we studied the effects of time since vaccination on influenza type/subtype-specific VE. We modelled influenza type/subtype-specific VE by time since vaccination using a restricted cubic spline, controlling for potential confounders (age, sex, time of onset, chronic conditions). Over 10,000 ILI cases were included in each analysis of influenza A(H3N2), A(H1N1)pdm09 and B; with 4,759, 3,152 and 3,617 influenza positive cases respectively. VE against influenza A(H3N2) reached 50.6% (95% CI: 30.0?65.1) 38 days after vaccination, declined to 0% (95% CI: -18.1?15.2) from 111 days onwards. At day 54 VE against influenza A(H1N1)pdm09 reached 55.3% (95% CI: 37.9?67.9) and remained between this value and 50.3% (95% CI: 34.8?62.1) until season end. VE against influenza B declined from 70.7% (95% CI: 51.3?82.4) 44 days after vaccination to 21.4% (95% CI: -57.4?60.8) at season end. To assess if vaccination campaign strategies need revising more evidence on VE by time since vaccination is urgently needed.
Tárgyszavak:Orvostudományok Egészségtudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:Euro surveillance. - 21 : 16 (2016), p. 1-12. -
További szerzők:Nunes, Baltazar Robertson, Chris Valenciano, Marta Reuss, Annicka Larrauri, Amparo Cohen, Jean Marie Oroszi Beatrix (1970-) (orvos, epidemiológus) Rizzo, Caterina Machado, Ausenda Pitigoi, Daniela Domegan, Lisa Paradowska-Stankiewicz, Iwona Buchholz, Udo Gherasim, Alin Daviaud, Isabelle Horváth Judit Krisztina Bella, Antonino Lupulescu, Emilia O'Donnell, Joan Korczyńska, Monika Moren, Alain I-MOVE case-control study team
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

4.

001-es BibID:BIBFORM103352
035-os BibID:(Scopus)84873314436
Első szerző:Kissling, Esther
Cím:Low and decreasing vaccine effectiveness against influenza A(H3) in 2011/12 among vaccination target groups in Europe : results from the I-MOVE multicentre case-control study / E. Kissling, M. Valenciano, A. Larrauri, B. Oroszi, J. M. Cohen, B. Nunes, D. Pitigoi, C. Rizzo, J. Rebolledo, I. Paradowska-Stankiewicz, S. Jiménez-Jorge, J. K. Horváth, I. Daviaud, R. Guiomar, G. Necula, A. Bella, J. O'Donnell, M. Głuchowska, B. C. Ciancio, A. Nicoll, A. Moren
Dátum:2013
ISSN:1560-7917
Megjegyzések:Within the Influenza Monitoring Vaccine Effectiveness in Europe (I-MOVE) project we conducted a multicentre case?control study in eight European Union (EU) Member States to estimate the 2011/12 influenza vaccine effectiveness against medically attended influenza-like illness (ILI) laboratory-confirmed as influenza A(H3) among the vaccination target groups. Practitioners systematically selected ILI / acute respiratory infection patients to swab within seven days of symptom onset. We restricted the study population to those meeting the EU ILI case definition and compared influenza A(H3) positive to influenza laboratory-negative patients. We used logistic regression with study site as fixed effect and calculated adjusted influenza vaccine effectiveness (IVE), controlling for potential confounders (age group, sex, month of symptom onset, chronic diseases and related hospitalisations, number of practitioner visits in the previous year). Adjusted IVE was 25% (95% confidence intervals (CI): -6 to 47) among all ages (n=1,014), 63% (95% CI: 26 to 82) in adults aged between 15 and 59 years and 15% (95% CI: -33 to 46) among those aged 60 years and above. Adjusted IVE was 38% (95%CI: -8 to 65) in the early influenza season (up to week 6 of 2012) and -1% (95% CI: -60 to 37) in the late phase. The results suggested a low adjusted IVE in 2011/12. The lower IVE in the late season could be due to virus changes through the season or waning immunity. Virological surveillance should be enhanced to quantify change over time and understand its relation with duration of immunological protection. Seasonal influenza vaccines should be improved to achieve acceptable levels of protection.
Tárgyszavak:Orvostudományok Egészségtudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:Eurosurveillance. - 18 : 5 (2013), p. 1-10. -
További szerzők:Valenciano, Marta Larrauri, Amparo Oroszi Beatrix (1970-) (orvos, epidemiológus) Cohen, Jean Marie Nunes, Baltazar Pitigoi, Daniela Rizzo, Caterina Rebolledo, J. Paradowska-Stankiewicz, Iwona Jiménez-Jorge, Silvia Horváth, J. K. Daviaud, Isabelle Guiomar, Raquel Necula, G. Bella, Antonino O'Donnell, Joan Głuchowska, M. Ciancio, Bruno Nicoll, A. Moren, Alain
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

5.

001-es BibID:BIBFORM103350
035-os BibID:(Scopus)76449094520 (WOS)000272247100007 (cikkazonosító)19388
Első szerző:Kissling, Esther
Cím:"I-MOVE" towards monitoring seasonal and pandemic influenza vaccine effectiveness : lessons learnt from a pilot multi-centric case-control study in Europe, 2008-9 / E. Kissling, M. Valenciano, J. M. Falcão, A. Larrauri, K. Widgren, D. Pitigoi, B. Oroszi, B. Nunes, C. Savulescu, A. Mazick, E. Lupulescu, B. Ciancio, A. Moren
Dátum:2009
ISSN:1025-496X 1560-7917
Megjegyzések:Within I-MOVE (European programme to monitor seasonal and pandemic influenza vaccine effectiveness (IVE)) five countries conducted IVE pilot case-control studies in 2008-9. One hundred and sixty sentinel general practitioners (GP) swabbed all elderly consulting for influenza-like illness (ILI). Influenza confirmed cases were compared to influenza negative controls. We conducted a pooled analysis to obtain a summary IVE in the age group of ?65 years. We measured IVE in each study and assessed heterogeneity between studies qualitatively and using the I2 index. We used a one-stage pooled model with study as a fixed effect. We adjusted estimates for age-group, sex, chronic diseases, smoking, functional status, previous influenza vaccinations and previous hospitalisations. The pooled analysis included 138 cases and 189 test-negative controls. There was no statistical heterogeneity (I2=0) between studies but ILI case definition, previous hospitalisations and functional status were slightly different. The adjusted IVE was 59.1% (95% CI: 15.3-80.3%). IVE was 65.4% (95% CI: 15.6-85.8%) in the 65-74, 59.6% (95% CI: -72.6 -90.6%) in the age group of ?75 and 56.4% (95% CI: -0.2-81.3%) for A(H3). Pooled analysis is feasible among European studies. The variables definitions need further standardisation. Larger sample sizes are needed to achieve greater precision for subgroup analysis. For 2009-10, I-MOVE will extend the study to obtain early IVE estimates in groups targeted for pandemic H1N1 influenza vaccination.
Tárgyszavak:Orvostudományok Egészségtudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:Eurosurveillance. - 14 : 44 (2009), p. 29-36. -
További szerzők:Valenciano, Marta Falcão, J. M. Larrauri, Amparo Widgren, K. Pitigoi, Daniela Oroszi Beatrix (1970-) (orvos, epidemiológus) Nunes, Baltazar Savulescu, Camelia Mazick, A. Lupulescu, Emilia Ciancio, Bruno Moren, Alain
Internet cím:Szerző által megadott URL
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

6.

001-es BibID:BIBFORM103358
035-os BibID:(cikkazonosító)e1000388 (WOS)000286594200004 (Scopus)79951650357
Első szerző:Valenciano, Marta
Cím:Estimates of Pandemic Influenza Vaccine Effectiveness in Europe, 2009-2010 : results of Influenza Monitoring Vaccine Effectiveness in Europe (I-MOVE) Multicentre Case-Control Study / Marta Valenciano, Esther Kissling, Jean-Marie Cohen, Beatrix Oroszi, Anne-Sophie Barret, Caterina Rizzo, Baltazar Nunes, Daniela Pitigoi, Amparro Larrauri Cámara, Anne Mosnier, Judith K. Horvath, Joan O'Donnell, Antonino Bella, Raquel Guiomar, Emilia Lupulescu, Camelia Savulescu, Bruno C. Ciancio, Piotr Kramarz, Alain Moren
Dátum:2011
ISSN:1549-1676
Megjegyzések:Background: A multicentre case-control study based on sentinel practitioner surveillance networks from seven European countries was undertaken to estimate the effectiveness of 2009-2010 pandemic and seasonal influenza vaccines against medically attended influenza-like illness (ILI) laboratory-confirmed as pandemic influenza A (H1N1) (pH1N1). Methods and findings: Sentinel practitioners swabbed ILI patients using systematic sampling. We included in the study patients meeting the European ILI case definition with onset of symptoms >14 days after the start of national pandemic vaccination campaigns. We compared pH1N1 cases to influenza laboratory-negative controls. A valid vaccination corresponded to >14 days between receiving a dose of vaccine and symptom onset. We estimated pooled vaccine effectiveness (VE) as 1 minus the odds ratio with the study site as a fixed effect. Using logistic regression, we adjusted VE for potential confounding factors (age group, sex, month of onset, chronic diseases and related hospitalizations, smoking history, seasonal influenza vaccinations, practitioner visits in previous year). We conducted a complete case analysis excluding individuals with missing values and a multiple multivariate imputation to estimate missing values. The multivariate imputation (n = 2902) adjusted pandemic VE (PIVE) estimates were 71.9% (95% confidence interval [CI] 45.6-85.5) overall; 78.4% (95% CI 54.4-89.8) in patients <65 years; and 72.9% (95% CI 39.8-87.8) in individuals without chronic disease. The complete case (n = 1,502) adjusted PIVE were 66.0% (95% CI 23.9-84.8), 71.3% (95% CI 29.1-88.4), and 70.2% (95% CI 19.4-89.0), respectively. The adjusted PIVE was 66.0% (95% CI -69.9 to 93.2) if vaccinated 8-14 days before ILI onset. The adjusted 2009-2010 seasonal influenza VE was 9.9% (95% CI -65.2 to 50.9). Conclusions: Our results suggest good protection of the pandemic monovalent vaccine against medically attended pH1N1 and no effect of the 2009-2010 seasonal influenza vaccine. However, the late availability of the pandemic vaccine and subsequent limited coverage with this vaccine hampered our ability to study vaccine benefits during the outbreak period. Future studies should include estimation of the effectiveness of the new trivalent vaccine in the upcoming 2010-2011 season, when vaccination will occur before the influenza season starts.
Tárgyszavak:Orvostudományok Egészségtudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:PLoS Medicine. - 8 : 1 (2011), p. 1-12. -
További szerzők:Kissling, Esther Cohen, Jean Marie Oroszi Beatrix (1970-) (orvos, epidemiológus) Barret, Anne-Sophie Rizzo, Caterina Nunes, Baltazar Pitigoi, Daniela Larrauri Cámara, Amparro Mosnier, Anne Horváth Judit Krisztina O'Donnell, Joan Bella, Antonino Guiomar, Raquel Lupulescu, Emilia Savulescu, Camelia Ciancio, Bruno Kramarz, Piotr Moren, Alain
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

7.

001-es BibID:BIBFORM103355
035-os BibID:(WOS)000355705700014 (Scopus)84929289547
Első szerző:Valenciano, Marta
Cím:The European I-MOVE Multicentre 2013-2014 Case-Control Study. Homogeneous moderate influenza vaccine effectiveness against A(H1N1)pdm09 and heterogenous results by country against A(H3N2) / Marta Valenciano, Esther Kissling, Annicka Reuss, Silvia Jiménez-Jorge, Judit K. Horváth, Joan M. O. Donnell, Daniela Pitigoi, Ausenda Machado, Francisco Pozo, I-MOVE Multicentre Case Control Study Team
Dátum:2015
ISSN:0264-410X
Megjegyzések:Background In the first five I-MOVE (Influenza Monitoring Vaccine Effectiveness in Europe) influenza seasons vaccine effectiveness (VE) results were relatively homogenous among participating study sites. In 2013?2014, we undertook a multicentre case-control study based on sentinel practitioner surveillance networks in six European Union (EU) countries to measure 2013?2014 influenza VE against medically-attended influenza-like illness (ILI) laboratory-confirmed as influenza. Influenza A(H3N2) and A(H1N1)pdm09 viruses co-circulated during the season. Methods Practitioners systematically selected ILI patients to swab within eight days of symptom onset. We compared cases (ILI positive to influenza A(H3N2) or A(H1N1)pdm09) to influenza negative patients. We calculated VE for the two influenza A subtypes and adjusted for potential confounders. We calculated heterogeneity between sites using the I2 index and Cochrane's Q test. If the I2 was <50%, we estimated pooled VE as (1 minus the OR) ? 100 using a one-stage model with study site as a fixed effect. If the I2 was >49% we used a two-stage random effects model. Results We included in the A(H1N1)pdm09 analysis 531 cases and 1712 controls and in the A(H3N2) analysis 623 cases and 1920 controls. For A(H1N1)pdm09, the Q test (p = 0.695) and the I2 index (0%) suggested no heterogeneity of adjusted VE between study sites. Using a one-stage model, the overall pooled adjusted VE against influenza A(H1N1)pdm2009 was 47.5% (95% CI: 16.4?67.0). For A(H3N2), the I2 was 51.5% (p = 0.067). Using a two-stage model for the pooled analysis, the adjusted VE against A(H3N2) was 29.7 (95% CI: ?34.4?63.2). Conclusions The results suggest a moderate 2013?2014 influenza VE against A(H1N1)pdm09 and a low VE against A(H3N2). The A(H3N2) estimates were heterogeneous among study sites. Larger sample sizes by study site are needed to prevent statistical heterogeneity, decrease variability and allow for two-stage pooled VE for all subgroup analyses.
Tárgyszavak:Orvostudományok Egészségtudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Influenza vaccine
Influenza vaccine effectiveness
Multicentre study
Test-negative design
Vaccine effectiveness
Megjelenés:Vaccine. - 33 : 24 (2015), p. 2813-2822. -
További szerzők:Kissling, Esther Reuss, Annicka Jiménez-Jorge, Silvia Horváth Judit Krisztina Donnell, Joan M. O. Pitigoi, Daniela Machado, Ausenda Pozo, Francisco Oroszi Beatrix (1970-) (orvos, epidemiológus) I-MOVE Multicentre Case Control Study Team
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Rekordok letöltése1